TP53 and colorectal cancer: Interestingly, Munro et al. [44] in a review based on 168 reports, including survival data of 18.766 patients, assessing p53 abnormalities and clinical outcomes in colorectal cancer found “no evidence for any relationship between the criterion used to define ‘positive’ by immunohistochemistry and outcome”.